(Nasdaq: COLL), a leading, diversified biopharmaceutical company, today announced updates to its Board of Directors and appointments of three new executive leaders as the Company drives a new ...

Klingbeil has decided not to seek re-election to the Company’s Board of Directors (the "Board") at the Company’s upcoming Annual Shareholder Meeting. Mr. Klingbeil will continue to serve as a ...